Cargando…
siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways
Breast cancer, the second leading cause of female deaths worldwide, is usually treated with cytotoxic drugs, accompanied by adverse side-effects, development of chemoresistance and relapse of disease condition. Survival and proliferation of the cancer cells are greatly empowered by over-expression o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164725/ https://www.ncbi.nlm.nih.gov/pubmed/29932151 http://dx.doi.org/10.3390/biomedicines6030073 |
_version_ | 1783359669198127104 |
---|---|
author | Kamaruzman, Nur Izyani Tiash, Snigdha Ashaie, Maeirah Chowdhury, Ezharul Hoque |
author_facet | Kamaruzman, Nur Izyani Tiash, Snigdha Ashaie, Maeirah Chowdhury, Ezharul Hoque |
author_sort | Kamaruzman, Nur Izyani |
collection | PubMed |
description | Breast cancer, the second leading cause of female deaths worldwide, is usually treated with cytotoxic drugs, accompanied by adverse side-effects, development of chemoresistance and relapse of disease condition. Survival and proliferation of the cancer cells are greatly empowered by over-expression or over-activation of growth factor receptors and anti-apoptotic factors. Identification of these key players that cross-talk to each other, and subsequently, knockdown with their respective siRNAs in a synchronous manner could be a promising approach to precisely treat the cancer. Since siRNAs demonstrate limited cell permeability and unfavorable pharmacokinetic behaviors, pH-sensitive nanoparticles of carbonate apatite were employed to efficiently carry the siRNAs in vitro and in vivo. By delivering selective siRNAs against the mRNA transcripts of the growth factor receptors, such as ER, ERBB2 (HER2), EGFR and IGFR, and anti-apoptotic protein, such as BCL2 in human (MCF-7 and MDA-MB-231) and murine (4T1) breast cancer cell lines, we found that ESR1 along with BCL-2, or with ERBB2 and EGFR critically contributes to the growth/survival of the cancer cells by activating the MAPK and PI-3 kinase pathways. Furthermore, intravenous delivery of the selected siRNAs aiming to suppress the expression of ER/BCL2 and ER/ERBB2/EGFR groups of proteins led to a significant retardation in tumor growth in a 4T1-induced syngeneic mouse model. |
format | Online Article Text |
id | pubmed-6164725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61647252018-10-11 siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways Kamaruzman, Nur Izyani Tiash, Snigdha Ashaie, Maeirah Chowdhury, Ezharul Hoque Biomedicines Article Breast cancer, the second leading cause of female deaths worldwide, is usually treated with cytotoxic drugs, accompanied by adverse side-effects, development of chemoresistance and relapse of disease condition. Survival and proliferation of the cancer cells are greatly empowered by over-expression or over-activation of growth factor receptors and anti-apoptotic factors. Identification of these key players that cross-talk to each other, and subsequently, knockdown with their respective siRNAs in a synchronous manner could be a promising approach to precisely treat the cancer. Since siRNAs demonstrate limited cell permeability and unfavorable pharmacokinetic behaviors, pH-sensitive nanoparticles of carbonate apatite were employed to efficiently carry the siRNAs in vitro and in vivo. By delivering selective siRNAs against the mRNA transcripts of the growth factor receptors, such as ER, ERBB2 (HER2), EGFR and IGFR, and anti-apoptotic protein, such as BCL2 in human (MCF-7 and MDA-MB-231) and murine (4T1) breast cancer cell lines, we found that ESR1 along with BCL-2, or with ERBB2 and EGFR critically contributes to the growth/survival of the cancer cells by activating the MAPK and PI-3 kinase pathways. Furthermore, intravenous delivery of the selected siRNAs aiming to suppress the expression of ER/BCL2 and ER/ERBB2/EGFR groups of proteins led to a significant retardation in tumor growth in a 4T1-induced syngeneic mouse model. MDPI 2018-06-22 /pmc/articles/PMC6164725/ /pubmed/29932151 http://dx.doi.org/10.3390/biomedicines6030073 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kamaruzman, Nur Izyani Tiash, Snigdha Ashaie, Maeirah Chowdhury, Ezharul Hoque siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways |
title | siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways |
title_full | siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways |
title_fullStr | siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways |
title_full_unstemmed | siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways |
title_short | siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways |
title_sort | sirnas targeting growth factor receptor and anti-apoptotic genes synergistically kill breast cancer cells through inhibition of mapk and pi-3 kinase pathways |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164725/ https://www.ncbi.nlm.nih.gov/pubmed/29932151 http://dx.doi.org/10.3390/biomedicines6030073 |
work_keys_str_mv | AT kamaruzmannurizyani sirnastargetinggrowthfactorreceptorandantiapoptoticgenessynergisticallykillbreastcancercellsthroughinhibitionofmapkandpi3kinasepathways AT tiashsnigdha sirnastargetinggrowthfactorreceptorandantiapoptoticgenessynergisticallykillbreastcancercellsthroughinhibitionofmapkandpi3kinasepathways AT ashaiemaeirah sirnastargetinggrowthfactorreceptorandantiapoptoticgenessynergisticallykillbreastcancercellsthroughinhibitionofmapkandpi3kinasepathways AT chowdhuryezharulhoque sirnastargetinggrowthfactorreceptorandantiapoptoticgenessynergisticallykillbreastcancercellsthroughinhibitionofmapkandpi3kinasepathways |